Additional Data Updates from AASLD 2023

EP: 1.The Evolving Landscape of Hepatocellular Carcinoma

EP: 2.Atezolizumab plus Bevacizumab in the Treatment of Unresectable HCC

EP: 3.AASLD 2023 Updates: HIMALAYA Trial for uHCC

EP: 4.Efficacy and Safety Outcomes in Combination Immunotherapy for uHCC

EP: 5.Real-World Data and Impact on Treatment Selection in uHCC

Now Viewing

EP: 6.Additional Data Updates from AASLD 2023

EP: 7.Future Directions in the Management of Hepatocellular Carcinoma

This is a video synopsis/summary of a Post-Conference Perspectives featuring Anwaar Saeed, MD, and Amit Singal, MD, MS.

Singal discusses an AASLD abstract examining clinical and imaging factors to predict risk of varices in hepatocellular carcinoma (HCC) patients, which can help determine need for pretreatment endoscopy before regimens like atezolizumab-bevacizumab. The model achieved a high negative predictive value, meaning it reliably identified low-risk patients unlikely to have varices. If validated, using it could avoid endoscopy in 50% of HCC cases.

Transitioning to emerging treatments, Saeed reviews phase 2 and phase 3 HCC study data presented at AASLD. A network meta-analysis found the regimens of sintilimab plus a bevacizumab biosimilar and camrelizumab-apatinib offered the best survival hazard ratios, followed by atezolizumab-bevacizumab and durvalumab-tremelimumab, which also showed efficacy vs sorafenib. However, she cautions that regional heterogeneity between trial populations limits head-to-head cross-study comparisons. A separate single-arm phase 2 study of tislelizumab- anlotinib reported encouraging response rate and disease control data, albeit in a trial where a number of patients had hepatitis B–associated HCC, a positive prognostic factor. Mature survival outcomes are still needed.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.